Advertisement


Greg D. Judy, MD, on Safety Incidents in Radiotherapy

2017 Quality Care Symposium

Advertisement

Greg D. Judy, MD, of UNC Health Care, discusses the contributing factors, and possible fixes, for near-miss and actual safety incidents in patients being treated with radiotherapy.



Related Videos

Issues in Oncology

Brian Weiss, MD, on Reducing Treatment Errors With Improvement Science

Brian Weiss, MD, of Cincinnati Children’s Hospital Medical Center, discusses a program designed to eliminate errors in chemotherapy use among pediatric patients whose regimens incorporate multiple drugs and rigorous monitoring schedules (Abstract 37).

Breast Cancer

Caleb Dulaney, MD, on Breast Cancer: Improving Online Patient Information

Caleb Dulaney, MD, of the University of Alabama at Birmingham, discusses ways to broaden and improve the quality of information that women with breast cancer find—in English and Spanish—on websites of nationally recognized cancer centers (Abstract 135).

Issues in Oncology

Blase N. Polite, MD, MPP: The Oncology Care Model in Academia

Blase N. Polite, MD, MPP, of the University of Chicago, discusses implementing the Oncology Care Model in an academic health center and the challenges of getting buy-in from faculty members.

Issues in Oncology

Gabrielle Rocque, MD, on The Oncology Care Model: Transforming Practices

Gabrielle Rocque, MD, of the University of Alabama at Birmingham, discusses the challenges of implementing Oncology Care Model requirements, such as providing treatment plans, and the opportunities to transform practices with improved workflow and patient outcomes.

Issues in Oncology
Lung Cancer

Thomas J. Smith, MD, on Oral Abstract Session B (2017 Quality Care Symposium)

Thomas J. Smith, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, summarizes two papers for which he was a discussant: reducing overuse of colony-stimulating factors without compromising the safety of patients with lung cancer receiving chemotherapy, and a cost-and-survival analysis before and after implementing Dana-Farber Clinical Pathways for patients with stage IV non–small cell lung cancer (Abstracts 3, 52).

Advertisement

Advertisement




Advertisement